KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Supernus Pharmaceuticals (SUPN) EBIAT: 2011-2025

Historic EBIAT for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to -$45.1 million.

  • Supernus Pharmaceuticals' EBIAT fell 217.20% to -$45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.1 million, marking a year-over-year decrease of 132.02%. This contributed to the annual value of $73.9 million for FY2024, which is 5512.84% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported EBIAT of -$45.1 million as of Q3 2025, which was down 300.53% from $22.5 million recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' EBIAT peaked at $38.5 million during Q3 2024, and registered a low of -$45.1 million during Q3 2025.
  • In the last 3 years, Supernus Pharmaceuticals' EBIAT had a median value of $1.2 million in 2023 and averaged $3.7 million.
  • Its EBIAT has fluctuated over the past 5 years, first spiked by 2,496.63% in 2024, then crashed by 9,637.90% in 2025.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' EBIAT stood at $2.4 million in 2021, then surged by 943.45% to $25.5 million in 2022, then crashed by 95.39% to $1.2 million in 2023, then surged by 1,204.51% to $15.3 million in 2024, then tumbled by 217.20% to -$45.1 million in 2025.
  • Its EBIAT was -$45.1 million in Q3 2025, compared to $22.5 million in Q2 2025 and -$11.8 million in Q1 2025.